

Vergessen? - Neues über Morbus Alzheimer

P. Entzian & A. Entzian

Literaturübersicht zum Beitrag PdN-BioS 4/63

Literatur

- [1] Maurer, K.: Auguste D. - URL: www.deutsche-alzheimer.de/index.php?id=106 (24.10.2013).
- [2] Alzheimer Forschung Initiative e.V.: Die Alzheimer-Krankheit. - URL: www.alzheimer-forschung.de/alzheimer-krankheit/index.htm (15.10.2013).
- [3] Magazin, P.M.: Alzheimer? - URL: www.pm-magazin.de/r/gute-frage/was-ist-der-unterschied-zwischen-demenz-und-alzheimer (05.10.2013).
- [4] alzheimerinfo.de: Was ist Demenz? Was ist Alzheimer? - URL: www.alzheimerinfo.de/alzheimer/demenz_alzheimer/index.jsp (20.10.2013).
- [5] Wikipedia: Subkortikale arteriosklerotische Enzephalopathie. - URL: de.wikipedia.org/wiki/Subkortikale_arteriosklerotische_Enzephalopathie (01.10.2013).
- [6] Stuhlmann, W.: Krankheitsbild und Verlauf der Demenzerkrankung. Geronet, (2005).
- [7] Plassman, B.L.; Langa, K.M.; Fisher, G.G.; Heeringa, S.G.; Weir, D.R.; Ofstedal, M.B.; Burke, J.R.; Hurd, M.D.; Potter, G.G.; Rodgers, W.L.; Steffens, D.C.; Willis, R.J.; Wallace, R.B.: Prevalence of dementia in the United States: the aging, demographics, and memory study. *Neuroepidemiology* 29, (2007), S. 125–132, doi: 10.1159/000109998.
- [8] Destatis: Gesundheit - Krankheitskosten. Statistisches Bundesamt R 7.2/FS 12, (2010), S. 1–45.
- [9] Bickel, H.: Das Wichtigste: Die Epidemiologie der Demenz. Deutsche Alzheimer Gesellschaft, (2010), S. 1–3.
- [10] Bickel, H.: Das Wichtigste: Die Epidemiologie der Demenz. Deutsche Alzheimer Gesellschaft, (2007), S. 1–3.
- [11] Kolonko, S.: Alzheimer oder Altersvergesslichkeit? - URL: www.wdr.de/tv/quarks/sendungsbeitraege/2008/1202/002_alzheimer.jsp (29.09.2013).
- [12] Deutsches Grünes Kreuz für Gesundheit: Uhrentest zur Früherkennung von Demenzerkrankungen. - URL: <http://dgk.de/gesundheit/verhalten-geist-psyche/alzheimer-demenz/uhrentest.html> (23.10.2013).
- [13] Klöppel, S.; Stonnington, C.M.; Chu, C.; Draganski, B.; Scahill, R.I.; Rohrer, J.D.; Fox, N.C.; Jack, C.R.; Ashburner, J.; Frackowiak, R.S.J.: Automatic classification of MR scans in Alzheimer's disease. *Brain* 131, (2008), S. 681–689, doi: 10.1093/brain/awm319.
- [14] Krzovska, M.: Basics Neurologie. 2. Aufl., Urban & Fischer, München (2009), ISBN: 978-3-437-42197-6.

- [15] Barthel, H.; Gertz, H.-J.; Dresel, S.; Peters, O.; Bartenstein, P.; Buerger, K.; Hiemeyer, F.; Wittemer-Rump, S.M.; Seibyl, J.; Reiningner, C.; Sabri, O.: Cerebral amyloid- β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. *Lancet Neurol* 5/10, (2011), S. 424–35, doi: 10.1016/S1474-4422(11)70077-1.
- [16] Bracco, L.; Gallato, R.; Grigoletto, F.; Lippi, A.; Lepore, V.; Bino, G.; Lazzaro, M.P.; Carella, F.; Piccolo, T.; Pozzilli, C.: Factors affecting course and survival in Alzheimer's disease. A 9-year longitudinal study. *Arch Neurol* 12/51, (1994), S. 1213–9.
- [17] Kern, S.: Wie verläuft die Alzheimer Demenz? Alzheimer Gesellschaft Baden-Württemberg, (2011).
- [18] Medline Plus: Memantine. - URL: www.nlm.nih.gov/medlineplus/druginfo/meds/a604006.html (15.10.2013).
- [19] Medline Plus: Donepezil. - URL: www.nlm.nih.gov/medlineplus/druginfo/meds/a697032.html (15.10.2013).
- [20] Medline Plus: Rivastigmine. - URL: www.nlm.nih.gov/medlineplus/druginfo/meds/a699058.html (15.10.2013).
- [21] Medline Plus: Galantamine. - URL: www.nlm.nih.gov/medlineplus/druginfo/meds/a699058.html (15.10.2013).
- [22] Förstl, H.: Antidementiva – wem nützen sie wirklich? *Internist* 49, (2008), S. 353–359, doi: 10.1007/s00108-007-1990-y.
- [23] Farlow, M.R.: NMDA receptor antagonists - A new therapeutic approach for Alzheimer's disease. *Geriatrics* 6/59, (2004), S. 22–27.
- [24] Mudher, A.; Lovestone, S.: Alzheimer's disease – do tauists and baptists finally shake hands? *Trends Neurosci* 1/25, (2002), S. 22–26, doi: 10.1016/S0166-2236(00)02031-2.
- [25] Hardy, J.; Allsop, D.: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends Pharmacol Sci* 1986/12, (1991), S. 383–388, doi: 10.1016/0165-6147(91)90609-V.
- [26] Nussbaum, J.M.; Schilling, S.; Cynis, H.; Silva, A.; Swanson, E.; Wangsanut, T.; Tayler, K.; Wiltgen, B.; Hatami, A.; Rönicke, R.; Reymann, K.; Hutter-Paier, B.; Alexandru, A.; Jagla, W.; Graubner, S.; Glabe, C.G.; Demuth, H.-U.; Bloom, G.S.: Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid- β . *Nature* 7400/485, (2012), S. 651–5, doi: 10.1038/nature11060.
- [27] Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.T.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O'Banion, M.K.; Pachter, J.; Pasinetti, G.; Carlos Plata-Salaman, J.R.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Muiswinkel, F.L. Van; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T.: Inflammation and Alzheimer's disease. *Neurobiol Aging* 3/21, (2000), S. 383–421, doi: 10.1016/S0197-4580(00)00124-X.

- [28] Iqbal, K.; Alonso, A.D.C.; Chen, S.; Chohan, M.O.; El-Akkad, E.; Gong, C.-X.; Khatoon, S.; Li, B.; Liu, F.; Rahman, A.; Tanimukai, H.; Grundke-Iqbal, I.: Tau pathology in Alzheimer disease and other tauopathies. *Biochim Biophys Acta* 2-3/1739, (2005), S. 198–210, doi: 10.1016/j.bbadis.2004.09.008.
- [29] Jakob-Roetne, R.; Jacobsen, H.: Die Alzheimer-Demenz: von der Pathologie zu therapeutischen Ansätzen. *Angew Chem* 17/121, (2009), S. 3074–3105, doi: 10.1002/ange.200802808.
- [30] Iwata, N.; Higuchi, M.; Saido, T.C.: Metabolism of amyloid-beta peptide and Alzheimer's disease. *Pharmacol Therapeut* 2/108, (2005), S. 129–48, doi: 10.1016/j.pharmthera.2005.03.010.
- [31] Ewers, M.; Morgan, D.G.; Gordon, M.N.; Woodruff-Pak, D.S.: Associative and motor learning in 12-month-old transgenic APP+PS1 mice. *Neurobiol Aging* 8/27, (2006), S. 1118–1128, doi: 10.1016/j.neurobiolaging.2005.05.019.
- [32] Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.: Long-term effects of A β 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. *Lancet* 9634/372, (2008), S. 216–223, doi: 10.1016/S0140-6736(08)61075-2.
- [33] Christensen, D.Z.; Kraus, S.L.; Flohr, A.; Cotel, M.-C.; Wirths, O.; Bayer, T.A.: Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. *Acta Neuropathol* 116, (2008), S. 647–655, doi: 10.1007/s00401-008-0451-6.
- [34] Walsh, D.M.; Klyubin, I.; Fadeeva, J. V; Cullen, W.K.; Anwyl, R.; Wolfe, M.S.; Rowan, M.J.; Selkoe, D.J.: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 416, (2002), S. 535–539, doi: 10.1038/416535a.
- [35] Gandy, S.; Simon, A.J.; Steele, J.W.; Lublin, A.L.; Lah, J.J.; Walker, L.C.; Levey, A.I.; Krafft, G.A.; Levy, E.; Checler, F.; Glabe, C.; Bilker, W.B.; Abel, T.; Schmeidler, J.; Ehrlich, M.E.: Days-to-criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. *Ann Neurol* 2/68, (2010), S. 220–30, doi: 10.1002/ana.22052.
- [36] Wirths, O.; Multhaup, G.; Bayer, T.A.: A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide - the first step of a fatal cascade. *J Neurochemi* 91, (2004), S. 513–520, doi: 10.1111/j.1471-4159.2004.02737.x.
- [37] Harigaya, Y.; Saido, T.C.; Eckman, C.B.; Prada, C.M.; Shoji, M.; Younkin, S.G.: Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. *Biochemi Bioph Res Co* 2/276, (2000), S. 422–427, doi: 10.1006/bbrc.2000.3490.
- [38] Schilling, S.; Lauber, T.; Schaupp, M.; Manhart, S.; Scheel, E.; Bo, G.; Demuth, H.-U.: On the Seeding and Oligomerization of pGlu-Amyloid Peptides (in vitro). *Biochemistry* 41/45, (2006), S. 12393–12399, doi: 10.1021/bi0612667.
- [39] Russo, C.; Violani, E.; Salis, S.; Venezia, V.; Dolcini, V.; Damonte, G.; Benatti, U.; Arrigo, C.D.; Patrone, E.; Carlo, P.; Schettini, G.: Pyroglutamate-modified amyloid β -peptides – A β N3(pE) –

- strongly affect cultured neuron and astrocyte survival. *J Neurochemi* 6/82, (2002), S. 1480–1489, doi: 10.1046/j.1471-4159.2002.01107.x.
- [40] Kuo, Y.-M.; Webster, S.; Emmerling, M.R.; Lima, N. De; Roher, A.E.: Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A β peptides of Alzheimer's disease. *Biochim Biophys Acta* 1406, (1998), S. 291–298, doi: 10.1016/S0925-4439(98)00014-3.
- [41] Schilling, S.; Zeitschel, U.; Hoffmann, T.; Heiser, U.; Francke, M.; Kehlen, A.; Holzer, M.; Hutter-Paier, B.; Prokesch, M.; Windisch, M.; Jagla, W.; Schlenzig, D.; Lindner, C.; Rudolph, T.; Reuter, G.; Cynis, H.; Montag, D.; Demuth, H.-U.; Rossner, S.: Glutaminy cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. *Nat med* 10/14, (2008), S. 1106–1111, doi: 10.1038/nm.1872.
- [42] Cynis, H.; Schilling, S.; Bodnár, M.; Hoffmann, T.; Heiser, U.; Saido, T.C.; Demuth, H.-U.: Inhibition of glutaminy cyclase alters pyroglutamate formation in mammalian cells. *Biochim Biophys Acta* 1764, (2006), S. 1618–1625, doi: 10.1016/j.bbapap.2006.08.003.
- [43] Schilling, S.; Niestroj, A.J.; Rahfeld, J.-U.; Hoffmann, T.; Wermann, M.; Zunkel, K.; Wasternack, C.; Demuth, H.-U.: Identification of human glutaminy cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators. *J Biol Chem* 50/278, (2003), S. 49773–49779, doi: 10.1074/jbc.M309077200.
- [44] Janelins, M.C.; Mastrangelo, M.A.; Oddo, S.; LaFerla, F.M.; Federoff, H.J.; Bowers, W.J.: Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. *J Neuroinflamm* 2, (2005), S. 23, doi: 10.1186/1742-2094-2-23.
- [45] Meda, L.; Cassatella, A.M.; Szendrei, I.G.; Otvos, J.L.; Baron, P.; Villalba, M.; Ferrari, D.; Rossi, F.: Activation of microglial cells by beta-amyloid protein and interferon-gamma. *Nature* 374, (1995), S. 647–650, doi: 10.1038/374647a0.
- [46] Cynis, H.: Untersuchungen zur Rolle der Glutaminy-Cyclase bei der pathologischen Bildung von Pyroglutamyl-Peptiden. , 2009, Dissertation - URL: digital.bibliothek.uni-halle.de/hs/content/titleinfo/473753.
- [47] Cynis, H.; Hoffmann, T.; Friedrich, D.; Kehlen, A.; Gans, K.; Kleinschmidt, M.; Rahfeld, J.-U.; Wolf, R.; Wermann, M.; Stephan, A.; Haegele, M.; Sedlmeier, R.; Graubner, S.; Jagla, W.; Müller, A.; Eichentopf, R.; Heiser, U.; Seifert, F.; Quax, P.H.A.; Vries, M.R. de; Hesse, I.; Trautwein, D.; Wollert, U.; Berg, S.; Freyse, E.-J.; Schilling, S.; Demuth, H.-U.: The isoenzyme of glutaminy cyclase is an important regulator of monocyte infiltration under inflammatory conditions. *EMBO molecular medicine*, (2011), doi: 10.1002/emmm.201100158.
- [48] Proost, P.; Struyf, S.; Couvreur, M.; Lenaerts, J.-P.; Conings, R.; Menten, P.; Verhaert, P.; Wuyts, A.; Damme, V.: Posttranslational Modifications Affect the Activity of the Human Monocyte Chemotactic Proteins MCP-1 and MCP-2: Identification of MCP-2(6–76) as a Natural Chemokine Inhibitor. *J Immunol* 8/160, (1998), S. 4034–4041.
- [49] hil: Demenz möglicherweise durch Stress mitbedingt. - URL: www.aerzteblatt.de/nachrichten/56049/Demenz-moeglicherweise-durch-Stress-mitbedingt?s=Alzheimer-Demenz (21.10.2013).

- [50] Johansson, L.; Guo, X.; Hällström, T.; Norton, M.C.; Waern, M.; Ostling, S.; Bengtsson, C.; Skoog, I.: Common psychosocial stressors in middle-aged women related to longstanding distress and increased risk of Alzheimer's disease: a 38-year longitudinal population study. *BMJ open* 9/3, (2013), S. 1–7, doi: 10.1136/bmjopen-2013-003142.
- [51] alzheimer-forschung.de: Diabetes und Alzheimer: Neue Forschungsergebnisse aus dem AFI-Netzwerk. - URL: www.alzheimer-forschung.de/alzheimer-krankheit/aktuelles.htm?showid=4021 (21.10.2013).
- [52] Yaffe, K.; Falvey, C.M.; Hamilton, N.; Harris, T.B.; Simonsick, E.M.; Strotmeyer, E.S.; Shorr, R.I.; Metti, A.; Schwartz, A. V: Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. *JAMA internal medicine* 14/173, (2013), S. 1300–1306, doi: 10.1001/jamainternmed.2013.6176.
- [53] Hughes, T.M.; Kuller, L.H.; Barinas-Mitchell, E.J.M.; Mackey, R.H.; McDade, E.M.; Klunk, W.E.; Aizenstein, H.J.; Cohen, A.D.; Snitz, B.E.; Mathis, C.A.; Dekosky, S.T.; Lopez, O.L.: Pulse wave velocity is associated with β -amyloid deposition in the brains of very elderly adults. *Neurology*, (2013), doi: 10.1212/01.wnl.0000435301.64776.37.
- [54] rme: Antihypertonika könnten Alzheimer-Demenz vorbeugen. - URL: www.aerzteblatt.de/nachrichten/56218/Antihypertonika-koennten-Alzheimer-Demenz-vorbeugen?s=Alzheimer-Demenz# (21.10.2013).
- [55] alzheimer-forschung.de: "Molekularer Link" zwischen Alzheimer und Krebs gefunden. - URL: www.alzheimer-forschung.de/alzheimer-krankheit/aktuelles.htm?showid=3198 (21.10.2013).
- [56] Venkataramani, V.; Rossner, C.; Iffland, L.; Schweyer, S.; Tamboli, I.Y.; Walter, J.; Wirths, O.; Bayer, T. a: Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. *The Journal of biological chemistry* 14/285, (2010), S. 10678–89, doi: 10.1074/jbc.M109.057836.
- [57] Musicco, M.; Adorni, F.; Santo, S. Di; Prinelli, F.; Pettenati, C.; Caltagirone, C.; Palmer, K.; Russo, A.: Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study. *Neurology* 4/81, (2013), S. 322–8, doi: 10.1212/WNL.0b013e31829c5ec1.
- [58] alzheimer-forschung.de: Krebs und Alzheimer: Gibt es einen wechselseitigen Schutz? - URL: www.alzheimer-forschung.de/alzheimer-krankheit/aktuelles.htm?showid=4054 (21.10.2013).
- [59] Frain, L.; Swanson, D.; Betensky, R.; Cho, K.; Gagnon, D.; Kowall, N.; Lu, K.P.; Gaziano, J.M.; Driver, J.: A Reduced Risk of Alzheimer's Disease is Associated with the Majority of Cancers in a National Cohort of Veterans. *Alzheimer's Association International Conference 2013*, (2013).
- [60] OTS/S: AAIC 2013: Risiko- und andere Faktoren für Alzheimer Demenz. - URL: www.springermedizin.at/artikel/35840-aaic-2013-risiko-und-andere-faktoren-fuer-alzheimer-demenz (21.10.2013).
- [61] alzheimer-forschung.de: Mit blauer Farbe gegen Alzheimer: Methylenblau in der Forschung. - URL: www.alzheimer-forschung.de/alzheimer-krankheit/aktuelles.htm?showid=3934 (21.10.2013).

- [62] Akoury, E.; Pickhardt, M.; Gajda, M.; Biernat, J.; Mandelkow, E.; Zweckstetter, M.: Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. *Angewandte Chemie (International ed. in English)* 12/52, (2013), S. 3511–5, doi: 10.1002/anie.201208290.
- [63] Oberg, K. a.; Ruysschaert, J.-M.; Azarkan, M.; Smolders, N.; Zerhouni, S.; Wintjens, R.; Amrani, A.; Looze, Y.: Papaya glutamine cyclase, a plant enzyme highly resistant to proteolysis, adopts an all-beta conformation. *Eur J Biochem* 1/258, (1998), S. 214–222, doi: 10.1046/j.1432-1327.1998.2580214.x.
- [64] Schilling, S.; Lindner, C.; Koch, B.; Wermann, M.; Rahfeld, J.-U.; Bohlen, A. von; Rudolph, T.; Reuter, G.; Demuth, H.-U.: Isolation and characterization of glutaminyl cyclases from *Drosophila*: evidence for enzyme forms with different subcellular localization. *Biochemistry* 46, (2007), S. 10921–10930, doi: 10.1021/bi701043x.
- [65] Schilling, S.; Hoffmann, T.; Rosche, F.; Manhart, S.; Wasternack, C.; Demuth, H.-U.: Heterologous expression and characterization of human glutaminyl cyclase: evidence for a disulfide bond with importance for catalytic activity. *Biochemistry* 41, (2002), S. 10849–10857, doi: 10.1021/bi0260381.
- [66] Carrillo, D.R.; Parthier, C.; Jänckel, N.; Grandke, J.; Stelter, M.; Schilling, S.; Boehme, M.; Neumann, P.; Wolf, R.; Demuth, H.-U.; Stubbs, M.T.; Rahfeld, J.-U.: Kinetic and structural characterization of bacterial glutaminyl cyclases from *Zymomonas mobilis* and *Myxococcus xanthus*. *Biol Chem* 12/391, (2010), S. 1419–1428, doi: 10.1515/BC.2010.130.
- [67] Böckers, T.M.; Kreutz, M.R.; Pohl, T.: Glutaminyl-Cyclase Expression in the Bovine/Porcine Hypothalamus and Pituitary. *J Neuroendocrinol* 6/7, (1995), S. 445–453, doi: 10.1111/j.1365-2826.1995.tb00780.x.
- [68] Sykes, P.A.; Watson, S.J.; Temple, J.S.; Bateman, R.C.: Evidence for tissue-specific forms of glutaminyl cyclase. *FEBS Lett* 455, (1999), S. 159–161, doi: 10.1016/S0014-5793(99)00872-8.
- [69] Abraham, G.N.; Podell, D.N.: Pyroglutamic acid. Non-metabolic formation, function in proteins and peptides, and characteristics of the enzymes effecting its removal. *Mol Cell Biochem* 38, (1981), S. 181–190, doi: 10.1007/BF00235695.
- [70] Schilling, S.; Hoffmann, T.; Wermann, M.; Heiser, U.; Wasternack, C.; Demuth, H.-U.: Continuous spectrometric assays for glutaminyl cyclase activity. *Anal Biochem* 1/303, (2002), S. 49–56, doi: 10.1006/abio.2001.5560.
- [71] Schilling, S.; Hoffmann, T.; Manhart, S.; Hoffmann, M.; Demuth, H.-U.: Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. *FEBS Lett* 1-3/563, (2004), S. 191–196, doi: 10.1016/S0014-5793(04)00300-X.
- [72] Huang, K.-F.; Liu, Y.-L.; Cheng, W.-J.; Ko, T.-P.; Wang, A.H.-J.: Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation. *P Natl Acad Sci USA* 37/102, (2005), S. 13117–13122, doi: 10.1073/pnas.0504184102.
- [73] Buchholz, M.; Heiser, U.; Schilling, S.; Niestroj, A.J.; Zunkel, K.; Demuth, H.-U.: The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. *J Med Chem* 49, (2006), S. 664–677, doi: 10.1021/jm050756e.

- [74] Buchholz, M.; Hamann, A.; Aust, S.; Brandt, W.; B, L.; Hoffmann, T.; Schilling, S.; Demuth, H.-U.: Inhibitors for Human Glutaminyl Cyclase by Structure Based Design and Bioisosteric Replacement. *J Med Chem* 52, (2009), S. 7069–7080, doi: 10.1021/jm900969p.
- [75] Huang, K.-F.; Wang, Y.-R.; Chang, E.-C.; Chou, T.-L.; Wang, A.H.-J.: A conserved hydrogen-bond network in the catalytic centre of animal glutaminyl cyclases is critical for catalysis. *Biochem J* 1/411, (2008), S. 181–190, doi: 10.1042/BJ20071073.
- [76] Cynis, H.; Rahfeld, J.-U.; Stephan, A.; Kehlen, A.; Koch, B.; Wermann, M.; Demuth, H.-U.; Schilling, S.: Isolation of an isoenzyme of human glutaminyl cyclase: retention in the Golgi complex suggests involvement in the protein maturation machinery. *J Mol Biol* 5/379, (2008), S. 966–980, doi: 10.1016/j.jmb.2008.03.078.
- [77] Stephan, A.; Wermann, M.; Bohlen, A. von; Koch, B.; Cynis, H.; Demuth, H.-U.; Schilling, S.: Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics. *FEBS J* 22/276, (2009), S. 6522–36, doi: 10.1111/j.1742-4658.2009.07337.x.
- [78] Rossjohn, J.; Cappai, R.; Feil, S.C.; Henry, A.; McKinstry, W.J.; Galatis, D.; Hesse, L.; Multhaup, G.; Beyreuther, K.; Masters, C.L.; Parker, M.W.: Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. *Nature structural biology* 4/6, (1999), S. 327–31, doi: 10.1038/7562.
- [79] Barnham, K.J.; McKinstry, W.J.; Multhaup, G.; Galatis, D.; Morton, C.J.; Curtain, C.C.; Williamson, N.A.; White, A.R.; Hinds, M.G.; Norton, R.S.; Beyreuther, K.; Masters, C.L.; Parker, M.W.; Cappai, R.: Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. *The Journal of biological chemistry* 19/278, (2003), S. 17401–7, doi: 10.1074/jbc.M300629200.
- [80] Hynes, T.R.; Randal, M.; Kennedy, L.A.; Eigenbrot, C.; Kossiakoff, A.A.: X-ray crystal structure of the protease inhibitor domain of Alzheimer's amyloid beta-protein precursor. *Biochemistry* 43/29, (1990), S. 10018–22, doi: 2125487.
- [81] Wang, Y.; Ha, Y.: The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. *Molecular cell* 3/15, (2004), S. 343–53, doi: 10.1016/j.molcel.2004.06.037.
- [82] Crescenzi, O.; Tomaselli, S.; Guerrini, R.; Salvadori, S.; D'Ursi, A.M.; Temussi, P.A.; Picone, D.: Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. *European journal of biochemistry / FEBS* 22/269, (2002), S. 5642–8.
- [83] Goodsell, D.S.: Amyloid-beta Precursor Protein. *RCSB Protein Data Bank*, (2006), doi: 10.2210/rcsb_pdb/mom_2006_7.
- [84] Mancía, F.; Shapiro, L.: ADAM and Eph: how Ephrin-signaling cells become detached. *Cell* 2/123, (2005), S. 185–7, doi: 10.1016/j.cell.2005.10.004.
- [85] Hong, L.; Tang, J.: Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis. *Biochemistry* 16/43, (2004), S. 4689–95, doi: 10.1021/bi0498252.
- [86] Lührs, T.; Ritter, C.; Adrian, M.; Riek-Loher, D.; Bohrmann, B.; Döbeli, H.; Schubert, D.; Riek, R.: 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. *Proceedings of the National Academy*

of Sciences of the United States of America 48/102, (2005), S. 17342–7, doi: 10.1073/pnas.0506723102.

- [87] Klauda, J.B.: Chlamydia Membrane model for Elementary Body. - URL: terpconnect.umd.edu/~jbklauda/research/download/eb-dyn-1-dyn69.pdb (03.10.2013).
- [88] Brooks, B.R.; Brooks, C.L.; Mackerell, A.D.; Nilsson, L.; Petrella, R.J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A.R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R.W.; Post, C.B.; Pu, J.Z.; Schaefer, M.; Tidor, B.; Venable, R.M.; Woodcock, H.L.; Wu, X.; Yang, W.; York, D.M.; Karplus, M.: CHARMM: the biomolecular simulation program. *Journal of computational chemistry* 10/30, (2009), S. 1545–614, doi: 10.1002/jcc.21287.
- [89] Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E.: UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* 13/25, (2004), S. 1605–1612, doi: 10.1002/jcc.20084.
- [90] Persistence of Vision Pty., Ltd.: Persistence of Vision Raytracer. - URL: www.povray.org/ (2009), Version: 3.6.2.